{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "12013 Treatment of Anthracycline Extravasation using Dexrazoxane 3.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "TREATMENT OF ANTHRACYCLINE EXTRAVASATION USING DEXRAZOXANE IN ADULTS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "12013"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All Trust staff members and Clinicians responsible for the delivery of anthracycline chemotherapy"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "2 July 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "1 July 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Trust Requirements, Essex Cancer Network Guidance and Peer Review Requirements"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Corporate Nurse"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lisa Villiers, Chemotherapy Nurse Consultant"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u25a1 MSE NHS Foundation Trust \u25a1 Basildon Hospital \uf0fcBroomfield Hospital \u25a1 Southend Hospital \u25a1 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Medicine Optimisation and Medicine Safety Group (virtual Chair's Action by Dr.Subrahmanyam Peddasomayajula"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "29 June 2020"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Alison Felton, Head of Pharmacy"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "29 June 2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "29 June 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Joint Document Management Group)"
                    },
                    {
                        "text": "Date: July 2020"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Trust Intranet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "12013 Treatment of Anthracycline Extravasation using Dexrazoxane 3.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 10,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Waseem Nagi"
                    },
                    {
                        "text": "Lead Clinician SACT governance group MEHT"
                    },
                    {
                        "text": "24 June 2020"
                    },
                    {
                        "text": "All SACT Clinicians"
                    },
                    {
                        "text": "MSE SACT Governance group"
                    },
                    {
                        "text": "Scott Randell"
                    },
                    {
                        "text": "Technical Services Lead"
                    },
                    {
                        "text": "Helen Ellis"
                    },
                    {
                        "text": "Pharmacy Senior Management Team"
                    },
                    {
                        "text": "Laura McEwan"
                    },
                    {
                        "text": "Lead Pharmacist Haematology and Oncology"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "04071 Policy for standards Infection Prevention Precautions 04072 Hand Hygiene 13004 Specialist Palliative Care Operational Policy 10120 Dignity in care policy 04080 Consent to Examination or Treatment Policy MEHT SACT Administration Policy ESMO Extravasation Guidelines"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 14,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lisa Villiers"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "16 May 2016"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Jennifer Joyce"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "May 2016"
                    },
                    {
                        "text": "2.1"
                    },
                    {
                        "text": "Lesley Stuart"
                    },
                    {
                        "text": "6 month extension granted to standardise across MSB"
                    },
                    {
                        "text": "20th May 2019"
                    },
                    {
                        "text": "2.2"
                    },
                    {
                        "text": "Sarah Ferguson"
                    },
                    {
                        "text": "4 month extension request due MSE standardisation"
                    },
                    {
                        "text": "22nd November 2019"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Lisa Villiers"
                    },
                    {
                        "text": "Full Review: Clear guidance in the management of an extravasation"
                    },
                    {
                        "text": "2 July 2020"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Index"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Pharmacy Aseptics Manufacturing Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 - Product information"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "text": "Appendix 3 - Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "The purpose of this policy is to provide guidance to clinicians and practitioners in the management of extravasation injuries caused by anthracycline chemotherapy using Dexrazoxane (Savene)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "This guideline does not provide information or guidance on the treatment or management of any other form of extravasation injury. A practitioner requiring this type of guidance should refer to the relevant documents on the MEHT Intranet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "To ensure that all cases of extravasation caused by anthracyclines are dealt with appropriately and safely. Minimising the potential for harm or injury to the patient from the extravasation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "To ensure that Dexrazoxane is used appropriately and safely in the management of extravasation events."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "This policy applies to all healthcare staff employed by the Trust on a substantive or temporary basis who are involved in the prescribing, supply and storage, preparation, administration and monitoring of chemotherapy agents used in the treatment of malignancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "This guideline applies to the use of Dexrazoxane in the treatment of anthracycline extravasation only and does not provide guidance for the management of any other type of extravasation. Information relating to the treatment of extravasation from other causes can be found on the MEHT Intranet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "Staff should act within their professional codes of practice and undertake training in accordance with the Mandatory Training Policy (Training Needs Analysis)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "The responsibilities of the different staff groups in relation to this guideline are as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Chief Executive is responsible for ensuring that systems are in place to ensure the safe Delivery of Cytotoxic Chemotherapy. This responsibility is delegated to the Chief Medical Officer."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Medical Director is responsible for ensuring compliance with the systems in place to ensure the safe delivery of cytotoxic chemotherapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Senior Management at the Trust must ensure that all managers and supervisory staff are familiar with, and adhere to, the Trust Policy and Guidelines for the safe delivery of cytotoxic chemotherapy for cancer patients. They must also provide clinical and corporate leadership in the control of chemotherapy risks in the Trust."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Lead chemotherapy Nurse is responsible with the on-call Oncologist/Haematologist for the initial assessment of the potential extravasation injury. The lead nurse will also ensure that if Dexrazoxone is required staff involved in the administration or, if required, its' preparation are competent to undertake this role. The lead chemotherapy nurse in conjunction with the chemotherapy nurse is also responsible for ensuring all reporting and relevant paperwork is completed and the consultant treating the patient is informed of this event."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "On-Call Oncologist/Haematologist must respond to a request to assess a potential anthracycline extravasation as soon as possible. Using clinical judgement and in consultation with the lead chemotherapy nurse decide whether to use Dexrazoxone and prescribe accordingly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Chemotherapy Nurse is responsible for the safe administration of chemotherapy in line with MEHT policies and procedures. The nurse will monitor the patient for signs of extravasation and alert clinical colleagues should this be suspected and then follow the procedure outlined in this guideline if appropriate. The nurse is also responsible with the lead chemotherapy nurse for the completion of all relevant paperwork and informing the patient's consultant of the incident."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "The Oncology Pharmacist is responsible for ensuring that the Savene\u00ae kit is available for use at all times. This will involve the checking of expiry dates and the reordering of a new kit should it be required, liaising with the manufacturers to ensure that costs are contained. The oncology pharmacist will also ensure that all usage of this agent is in line with the licensed indications for the product and this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "The Pharmacy Aseptic Unit Staff must ensure that when called upon to prepare Dexrazoxone they respond quickly and efficiently to minimise harm to the patient. They will ensure that they work to agreed SOPs within their licence."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Extravasation is the inappropriate or accidental administration of chemotherapy into the subcutaneous or sub-dermal tissues surrounding the administration site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "Extravasation is possible with any intravenous injection, the degree of tissue damage after extravasation depends on the type of drug, its concentration and the amount extravasated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Anthracyclines are vesicant drugs, which in extravasation can cause severe tissue necrosis. They are also DNA-binding agents which in extravasation can result in late recognition of injury and poor healing leading to chronic injury."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "Dexrazoxane (Savene\u00ae) is a systemic antidote for the treatment of anthracycline extravasation. It is itself a cytotoxic agent having a dual mechanism of action involving the inhibition of DNA topoisomerase II and the chelation of iron thus reducing iron-dependant free radical oxidative stress associated with anthracycline induced toxicity."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": "Dexrazoxane must only be prepared and administered by staff who have received appropriate training and are competent to handle cytotoxic medication."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "Delays in recognition and treatment of extravasation increase the likelihood of tissue necrosis. Comprehensive treatment and expert advice is essential in reducing the likelihood of serious injury, ideally within 10 minutes of injury, preferably within 1hour and definitely within 24 hours. After  hours treatment philosophy changes from active \u2018curative' treatment to a damage limitation exercise"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "If an extravasation of an anthracycline is suspected this should be confirmed by the on-call consultant oncologist and the nurse in charge of the chemotherapy unit before Dexrazoxone is used."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 1,
                "prefix": 7.3,
                "text": "If there is a suspected extravasation or other drugs have been involved and it is not clear which drug has caused the extravasation then dexrazoxone should not be used."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 7.4,
                "text": "In all cases of definite and clinician confirmed non-liposomal anthracycline extravasation dexrazoxone should be used irrespective of the volume of drug extravasated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 7.5,
                "text": "Efficacy of dexrazoxone with liposomal preparations is not conclusive. It is possible that the liposomal capsule delays the uptake into adjacent tissues and hence the damage from free radical production is prevented (Cabriales et al 1998). If dexrazoxone cannot penetrate the liposome then it is likely to be less effective or even completely ineffective, and therefore this group of anthracycline patients should be excluded from treatment with Savene."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 7.6,
                "text": "Management and administration of Dexrazoxone when pharmacy aseptics unit is open: (this procedure is to be read alongside and in conjunction with the general directions for the management of extravasation as detailed in the procedure.)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "The Savene\u00ae kit is kept in the Aseptic unit store room. During Pharmacy aseptic opening hours reconstitution will be undertaken in the aseptics unit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "text": "When an anthracycline extravasation has been confirmed by the nurse in charge and the on-call consultant oncologist the oncologist will prescribe a three day course of dexrazoxone as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "The first infusion must be administered within 6 hours of the extravasation occurring."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "As soon as the extravasation has been confirmed the treating nurse should contact the pharmacy aseptic unit on bleep # 6555 2184 to advise them that dexrazoxone is required"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "The aseptics team will prepare the infusion (for preparation guidelines see Appendix 1) giving it an appropriate batch number and expiry as defined in local protocols."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "Once prepared the aseptics team will arrange for it to be transported urgently to the chemotherapy day unit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "If subsequent doses are required when the Aseptic unit is not open, vials for preparation of doses for days 2 and 3 will be taken to the chemotherapy suite at the same time as dose 1 is delivered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "Dexrazoxone is a cytotoxic agent, therefore disposal and safe handling requirements are as for any other cytotoxic agent."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "prefix": 7.7,
                "text": "Management and administration of Dexrazoxone when pharmacy aseptics unit is closed: (this procedure is to be read alongside and in conjunction with the general directions for the management of extravasation as detailed in the procedure.)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "Chemotherapy is very rarely administered at times when the pharmacy aseptics unit is closed so it is probable that the 1st dose of Dexrazoxone will always be prepared by pharmacy. However if the 2nd and 3rd days fall over a weekend or Bank Holiday it is likely that an alternative means of preparation will be required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "Whenever possible the Dexrazoxone infusion should be prepared by pharmacy in the aseptic unit and the policy outlined above must be followed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "If the initial extravasation occurs after the Aseptics Unit has closed the chemotherapy nurse must contact the main pharmacy urgently \u2013 up until 6pm by calling ext 4175 and request that the Savene\u00ae kit is released to them immediately. The nurse should come to pharmacy (A105) to collect the kit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "If the main pharmacy department is closed the on-call pharmacist should be contacted via switchboard."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "In the event that the aseptics unit is closed Dexrazoxone may be prepared in the chemotherapy unit using a closed system device."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "prefix": -8.0,
                "text": "Once reconstituted the Dexrazoxone should be used immediately, if storage is required it should be kept at between 2\u2070\u2070C for no more than 4 hours."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "In all other aspects the procedure to be followed is the same as outlined above."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "prefix": 7.8,
                "text": "Relevant Trust documentation should be completed and filed appropriately (e.g., Critical Incident form, patient database, medical notes, hand held records). Nursing staff should follow up the patient over the next month (either by phone or visit to department) as sometimes extravasation injuries can take a while to show. Complete extravasation follow up sheet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "prefix": 7.9,
                "text": "Report the incident through the Datix system."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "The patient's Consultant Oncologist/Haematologist must be informed of the incident as soon as possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "prefix": 7.11,
                "text": "Clinical trial results indicate that dexrazoxone is a safe and well tolerated agent, however all adverse events associated with or suspected to be due to this agent should be reported to the MHRA using a yellow card - available in the back of the current BNF or on-line www.yellowcard.mhra.gov.uk"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "These guidelines must be present in all areas where anthracycline chemotherapy is administered or prepared this will be audited by pharmacy. It will be on the intranet and MEHT website."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "The guidance will be communicated to all relevant staff at staff meetings and training sessions delivered by senior chemotherapy nurses, pharmacy staff or via company delivered training sessions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "The oncology pharmacist will monitor the use of this agent and compliance with these guidelines."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "The oncology pharmacist will monitor the use of this agent ensuring that a stock is always available for use, and that any use is in line with this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 9.2,
                "text": "The pharmacy department will retain preparation records for all batches prepared in line with their current SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 9.3,
                "text": "Chemotherapy nursing staff will maintain patient level records of all incidents where this agent is used and those where it was considered in the chemotherapy notes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Approval and Implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "All policies, procedures and guidelines will be approved by the Medicines Optimisation and Medication Safety Group, which is the specialist group with the authority to approve local pharmacy guidelines. These will then be submitted for ratification with the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "Once the document is ratified the author will be notified and the document will be uploaded to the Intarnet. It will be the author's responsibility to notify the Medicines Optimisation and Medication Safety Group of the approved policy/guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 1,
                "prefix": 11.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 1,
                "text": "(Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 1,
                "text": "ESMO guidelines on the Management of Extravasation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "MEHT SACT Administration Policy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "text": "Sussex Cancer Network \u2013 Guidelines for the Prevention and Treatment of Extravasation of Chemotherapy Drugs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 1,
                "text": "The Cytotoxic Handbook"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 1,
                "text": "Cabriales C, Breshnan J et al (1998) Extravasation of Liposomal Daunorubicin in patients with AIDS associated Kaposi's Sarcoma: A report of four cases. OncolNursForum 25(1):67-70"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "text": "Savene summary of product characteristics updated on eMC 27/01/2020 Royal Marsden \u2013Preparation of Savene using Phaseal device"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "text": "Data on file SpePharm UK Ltd."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 1,
                "text": "APPENDIX 1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "Only an approved reconstitution record is to be used in the manufacture or preparation of any product within the aseptic unit as detailed in unit procedures and in line with licensing requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "Reconstitution guidelines and the current approved master version of the worksheet, (reference Savene) can be located in the filing cabinet in the aseptic documentation room, containing chemotherapy worksheets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "Completion of all documentation and subsequent manufacture and checking and release will be undertaken following current standard operating guidelines (SOP) for the unit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "The use of the aseptic facility must only be undertaken by staff trained in the operation of the unit and equipment within and staff must adhere to the unit SOP's for the use of the facility."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "Full details on reconstitution and labelling of prepared dose are included on the worksheet."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "Labels for prepared doses are to be generated using the Episys computer system, as directed in the SOP for the unit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 1,
                "text": "APPENDIX 2 \u2013 Product and Storage information for Savene\u00ae"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "For the most up to date and comprehensive information on Savene\u00ae please refer to the latest summary of product characteristics available at:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "http://www.medicines.org.uk/EMC/medicine/22849/SPC/Savene/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "Product type:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "Savene\u00ae is presented as a white to off-white powder the supplied diluent is a clear isotonic liquid."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "The reconstituted solution is slightly yellow"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "Storage:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "Before dilution the powder should be stored at room temperature (below 25\u2070C) and protected from light in the original cardboard carton"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "Following reconstitution the resulting diluted solution should be used immediately but when necessary may be stored for up 4 hours in a fridge at 2-"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "\u2070C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "Special Precautions:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "Caution must be exercised when handling and preparing the reconstituted solution and the normal procedures for proper handling of cytotoxic medicinal products should be adopted."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "If the powder or solution contacts the skin or mucous membranes, wash immediately and thoroughly with water."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "Any unused product or waste material should be disposed of in accordance with Trust policy for disposal of cytotoxic waste."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "Treatment of Anthracycline Extravasation using Dexrazoxane in Adults/12013/3.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "Treatment of Anthracycline Extravasation using Dexrazoxane in Adults/12013/3.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Treatment of Anthracycline Extravasation using Dexrazoxane in Adults/12013"
            }
        },
        {
            "type": "table",
            "sequence_num": 102,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Updated guidance"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Clear guidance in the management of an extravasation"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Yes; Refer to pages 1 & 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 104,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lisa Villiers"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Nurse Consultant"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "June 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Page  of"
            }
        }
    ]
}